Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (August 2026)
37 slides from Context Therapeutics's investor presentation, August 2026
Slide 1: Advancing T Cell Engagers for Solid Tumors
Advancing T Cell Engagers for Solid Tumors Corporate Presentation August 2026
Slide 2: Forward Looking Statement Important Notice and Disclaimers
Executive Summary Forward Looking Statement Important Notice and Disclaimers This presentation contains “forward-looking statements” within the meaning of the Private Certain information contained in this presentation relates to or is based on studies, publications, Securities Litigation Reform Act
Slide 3: Pipeline Overview
Executive Summary Pipeline Overview PROGRAM TARGET LEAD INDICATION(S) PRECLINICAL PHASE 1 PHASE 2 ANTICIPATED MILESTONES Platinum resistant Q1 2027: Initiate Phase 1b CTIM-76 Claudin 6 Fast Track Designation ovarian cancer Q2 2027: Phase 1a initial Q3W dosing data Urothelial, colorectal, Q3 2026: Ph
Slide 4: Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers
Executive Summary Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers Potential to expand into early treatment lines through synergistic drug combinations Optimized Novel Monotherapies Synergistic Combination Approaches CTIM-76 CT-202 TCE + ADC TCE + PD-1xVEGF + +
Slide 5: T Cell Engager Strategy
T Cell Engager Strategy 5 C o n t e xt T h e r a p e u t i c s I n c . - A u g u s t 2 0 2 6
Slide 6: T Cell Engaging (TCE) Bispecific Antibodies
T Cell Engager Strategy T Cell Engaging (TCE) Bispecific Antibodies TCE-mediated Cancer Cell Death Mechanism of Action CD3 T-cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T T Cell lymphocytes toward malignant cells. TCE Bispecific Antibody These molecules simultaneous
Slide 7: 10 FDA Approvals for TCE for Solid and Liquid Tumors
T Cell Engager Strategy 10 FDA Approvals for TCE for Solid and Liquid Tumors Recently approved TCE have had strong initial commercial launches 2014 2022 2023 2024 2025 Product Target 2025 Revenue1 Blincyto CD19 x CD3 $1,559 million Tecvayli BCMA x CD3 $670 million Imdelltra DLL3 x CD3 $627 million T
Slide 8: TCE Success in Solid Tumors
T Cell Engager Strategy TCE Success in Solid Tumors Select programs highlighting efficacy in cold tumors with a low rate of cytokine release syndrome (CRS) Tarlatamab Pasritamig Xaluritamig Ubamatamab Asset IBI389 VIR-5500 (AMG757) (JNJ-78278343) (AMG509) (REGN4018) Company Target x Effector DLL3 x
Slide 9: CTIM-76
CTIM-76 CLDN6 x CD3 bispecific antibody 9 C o n t e xt T h e r a p e u t i c s I n c . - A u g u s t 2 0 2 6
Slide 10: CLDN6 Therapies Have the Potential to Reach a Large Patient Population
CTIM-76 Program CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the United States in Relapse/Refractory (R/R) Setting Patient Selected Cancer Incidence CLDN6 CLDN6 Population R/R Incidence indications (US Only) Positive Med/High Based on R/R Incide
Slide 11: CLDN6 is an Attractive Target for Immunotherapy
CTIM-76 Program CLDN6 is an Attractive Target for Immunotherapy CLDN6 is an Ideal TCE Target Avoiding CLDN3 and CLDN4 is a Critical Safety Determinant • CLDN6 is an oncofetal protein. Normally present at higher CLDN9 levels during embryonic development CLDN6 CLDN4 • Turned off or have low levels of
Slide 12: CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody
CTIM-76 Program CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) doma
Slide 13: Positive Phase 1a Clinical Data Observed with CTIM-76 Weekly Dosing
CTIM-76 Program Positive Phase 1a Clinical Data Observed with CTIM-76 Weekly Dosing CTIM-76 has been granted FDA Fast Track Designation Clinical Activity Low Rate of CRS Pan-PROC Target in Late Line PROC 7 (5-16) prior lines of therapy in PROC 29% confirmed ORR ~75% of platinum resistant 11% Grade 1
Slide 14: Significant Market Opportunity in High Unmet Need CLDN6+ Post-ADC PROC
CTIM-76 Program Significant Market Opportunity in High Unmet Need CLDN6+ Post-ADC PROC • ~75% of PROC patients are CLDN6+ Broad Use Case as Monotherapy or Combination • No approved treatment option specifically for this CTIM-76 CTIM-76 + ADC biomarker selected PROC population • ~42,000 CLDN6+ PROC p
Slide 15: Phase 1 Study Design
CTIM-76 Program Phase 1 Study Design An open-label, multi-center, dose escalation / expansion, safety, and PK study Screening Phase 1a Dose Escalation (QW Dosing) Phase 1a Dose Escalation (Q3W Dosing) 3+3 Design (Completed) 3+3 Design & Backfill (Ongoing) Key Inclusion Criteria • CLDN6+ positive via
Slide 16: CTIM-76 Exhibits Compelling Pharmacokinetic (PK) Properties
CTIM-76 Program CTIM-76 Exhibits Compelling Pharmacokinetic (PK) Properties Weekly Dosing (QW) Every Three Week (Q3W) PK Simulation 210 and 280µg doses displayed optimal PK properties, including Cmax Reducing TCE dose frequency has been shown to reduce T cell exhaustion, below target saturation (EC9
Slide 17: Patient Demographics at QW Target Doses of 140 to 280 µg
CTIM-76 Program Patient Demographics at QW Target Doses of 140 to 280 µg CTIM-76 evaluated in heavily pre-treated patients with high tumor burden Baseline Characteristics All Comers Baseline Characteristics Ovarian N 13 N 9 Age, n (range) 61 (29-72) Age, n (range) 63 (53-72) ECOG, n (range) 1 (0-1)
Slide 18: Safety Analysis at QW Target Doses of 140 to 280 µg
CTIM-76 Program Safety Analysis at QW Target Doses of 140 to 280 µg Observed to be well-tolerated with a favorable safety profile • Adverse events (AE) generally occurred during the first or second dose • Most events were low grade, of short duration, and were reversible with standard management • L
Slide 19: CRS in PROC Patients at Target Dose Levels
CTIM-76 Program CRS in PROC Patients at Target Dose Levels Benchmarking CRS profiles across approved and experimental TCE Grade 1 Grade 2 Grade 3 60% 50% Low CRS rates may be driven by both programs having tumor restricted targets and utilizing step 40% dosing plus steroid prophylaxis CRS Rate 30% 2
Slide 20: Interim Phase 1a Data at QW Target Doses
CTIM-76 Program CTIM-76 Interim Phase 1a Data at QW Target Doses Tumor reduction combined with manageable CRS profile supports continued clinical development 20% Best Overall % Change in • Dose proportional anti-tumor activity T O O O O Tumor Size From Baseline* • Tumor shrinkage across multiple les
Slide 21: Anti-tumor Activity at QW Target Dose Levels
CTIM-76 Program CTIM-76 Anti-tumor Activity at QW Target Dose Levels Emerging durability signal, despite weekly dosing during escalation phase Spider Plot 20 Step Dose Cohort All Ovarian 70/140 µg Comers 70/210 µg 0 Patient enrolled, n 13 9 140/280 µg On treatment RECIST evaluable, n 10 7 Change fro
Slide 22: CTIM-76 Antitumor Activity at QW Target Dose Levels
CTIM-76 Program CTIM-76 Antitumor Activity at QW Target Dose Levels Emerging durability signal with the potential to further improve with less frequent CTIM-76 dosing Months on Treatment Prior Indication Dose 1 2 3 4 5 6 7 8 9 10 11 Rx Testicular 3 280 Ovarian 5 280 Ovarian 5 140 Ovarian 7 210 Ovari
Slide 23: Significant RECIST Response in Ovarian Patient with Liver Lesions
CTIM-76 Program Significant RECIST Response in Ovarian Patient with Liver Lesions Baseline Week 9 Week 16 CA125 3108 ng/mL CA125 272 ng/mL CA125 166 ng/mL 95% Patient Case Study Detail CA125 Decline • PROC patient administered 140µg QW • 53-year-old female • High disease burden; liver and peritoneum
Slide 24: Competitive Profile for CTIM-76 in PROC
CTIM-76 Program Competitive Profile for CTIM-76 in PROC Encouraging tumor response and safety profile in heavily pretreated / ADC-experienced patient population CTIM-76 Multiple Azenosertib Brenetafusp Target CLDN6 CDH6, FRα, NaPi2b Wee1 PRAME (CCNE1 amplified) Format TCE ADC Small Molecule TCE Prio
Slide 25: CT-202
CT-202 Nectin-4 x CD3 bispecific antibody 25 C o n t e xt T h e r a p e u t i c s I n c . - A u g u s t 2 0 2 6
Slide 26: Nectin-4 Therapies Have the Potential to Reach a Large Patient Population
CT-202 Program Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapse/Refractory (R/R) Setting Patient Selected Cancer Incidence Nectin-4 Nectin-4 Population R/R Incidence indications (US Only) Positive Med/High Based on R
Slide 27: CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody
CT-202 Program CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design incorporating logic gating to spare Nectin-4 in normal tissue α-Nectin-4 • Because of its expression in healthy epidermal keratinocytes, sweat glands, and Fab hair follicles, Nectin-4 targeted treatments are
Slide 28: Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin
CT-202 Program Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin Logic Gating Through pH Dependency Increased Target Selectivity Through Avidity 30x gain of activity in acidic tumor microenvironment versus healthy cells1 High on-/off-rate when bound Avidity-enhanced to Nectin-4 monomer
Slide 29: CT-202 is Designed to Optimize Tumor Selectivity and Minimize Off-tumor Toxicity
CT-202 Program CT-202 is Designed to Optimize Tumor Selectivity and Minimize Off-tumor Toxicity Minimize Activity in Normal Tissues at pH7.4 Potency is Correlated With Target Density Impressive Tolerability and PK in NHP T cell activation at low pH(6.0) and normal pH(7.4) with T cell activation by c
Slide 30: CT-202 is Highly Active and Well Tolerated Across In Vivo Models
CT-202 Program CT-202 is Highly Active and Well Tolerated Across In Vivo Models Complete Tumor Regressions Reduced off-tumor T cell activation CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft CT-202 treatment resulted in significantly lower IL-6 induction compared to an enfortum
Slide 31: Phase 1 Study Design
CT-202 Program Phase 1 Study Design An open-label, multi-center, dose escalation / expansion, safety, and PK study Screening Phase 1a Dose Escalation (Q2W Dosing) Phase 1b Dose Expansion Bayesian Optimal Interval (BOIN) Design & Backfill Dose Optimization Key Inclusion Criteria • Patients with advan
Slide 32: CT-202 Competitive Landscape
CT-202 Program CT-202 Competitive Landscape Competitor TCE programs lack conditional activation, avidity enhancement, and high potency immune activator Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Marengo Therapeutics Henlius Asset CT-202 BT74801,2 RNDO-5643 TriSTAR07014 HLX-
Slide 33: Corporate
Corporate 33 C o n t e xt T h e r a p e u t i c s I n c . - A u g u s t 2 0 2 6
Slide 34: Experienced Leadership Team
Corporate Experienced Leadership Team Martin Lehr Karen Chagin, MD Chief Medical Officer CEO and Director Focus on Execution Experienced management team Jennifer Minai Alex Levit, Esq Clinical team has developed T cell Chief Financial Officer Chief Legal Officer therapies Our management team is supp
Slide 35: Investment Highlights (Nasdaq: CNTX)
Corporate Investment Highlights (Nasdaq: CNTX) Large High-Value Anticipated Strong Cash Unmet Need Targets Milestones Team Runway Solid Tumors Claudin 6 CTIM-76 Deep oncology Expected + Ph 1a initial Q3W dosing experience cash runway + data Q2 2027 into Q4 2027 Nectin-4 + ADC Resistance Focus on CT-
Slide 36: Advancing T Cell Engagers for Solid Tumors
Advancing T Cell Engagers for Solid Tumors © Context Therapeutics 2026
Slide 37: Glossary
Appendix Glossary ADC Antibody drug conjugate MTD Maximum tolerated dose AE Adverse event N.D. Not disclosed CAR-T Chimeric antigen receptor T cell therapy ORR Overall response rate CD3 Cluster of differentiation 3 PFS Progression free survival CLDN Claudin PK Pharmacokinetic CRS Cytokine release sy
Context Therapeutics — Investor Presentation (August 2026) on 6ix